Methotrexate

Form: Oral tablets, Injection (IV and IM)

Strength: Tablets: 2.5 mg, 5 mg, 10 mg, 15 mg; IV/IM: 25 mg/mL

Reference Brands: Trexall®, Rheumatrex® (EU & US)

Category: Oncology Cancer Care

Methotrexate, marketed under brand names like Trexall® and Rheumatrex®, is an essential chemotherapy drug and immunosuppressant used in the treatment of various oncologic conditions such as leukemia, lymphoma, breast cancer, and osteosarcoma. Available in oral and injectable forms, with strengths ranging from 2.5 mg to 25 mg/mL, Methotrexate is sourced globally by B2B pharmaceutical suppliers. It is GMP-compliant, ensuring consistent quality for hospitals and oncology centers. Methotrexate's wide availability in the US and EU supports effective cancer care at competitive pricing, making it a trusted option for treating aggressive cancers and autoimmune disorders.